Dr. Shin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-778-1900Fax+1 404-778-5520
Summary
- I am a professor of medical oncology focusing on the patient care and research in head and neck cancer and thyroid cancer.
And I am also a translational physician scientist focusing on drug discovery with nanotechnology and cancer prevention with natural compounds, and biomarker studies. I have had peer reviewed funding over the decades for such research and published more than 390 research articles.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1982 - 1985
Yonsei University College of MedicineClass of 1975
Certifications & Licensure
CA State Medical License 2012 - 2026
GA State Medical License 2003 - 2025
PA State Medical License 2001 - 2004
TX State Medical License 1987 - 2003
IL State Medical License 1983 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Member of EUAS European Union of Academy of Science, 2018
- FAAAS American Association of Advancement of Science, 2016
- KBS Global Award in Science and Technology Korea Broadcasting System (KBS), 2015
- Join now to see all
Clinical Trials
- Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2003 Nov 26
- Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
- Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck Start of enrollment: 2010 Mar 01
Publications & Presentations
PubMed
- DNA methylation profiles of cancer-related fatigue associated with markers of inflammation and immunometabolism.Canhua Xiao, Gang Peng, Karen N Conneely, Hongyu Zhao, Jennifer C Felger
Molecular Psychiatry. 2025-01-01 - Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.Nabil F Saba, Ritu Chaudhary, Kedar Kirtane, Angelo Marra, Asari Ekpenyong
Clinical Cancer Research. 2024-10-15 - Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression.Hussein Sabit, Borros Arneth, Shaimaa Abdel-Ghany, Engy F Madyan, Ashraf H Ghaleb
Cells. 2024-10-09
Journal Articles
- Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative AnalysisRathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
- Interleukin-6/STAT3 Signaling Is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell CarcinomaNabil F Saba, Dong M Shin, Head and Neck Pathology
- Article MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationGuojing Zhang, Fadlo R Khuri, Taofeek K Owonikoko, Dan Li, Conor E Steuer, Nabil F Saba, Dong M Shin, Sagar Lonial, ScienceDirect
Press Mentions
Research Roundup: Recent Grants and Publications for Emory Faculty and StaffMay 22nd, 2023- Shop TalkFebruary 10th, 2015
New Drug Combination Could Prevent Head and Neck Cancer in High-Risk PatientsFebruary 19th, 2013- Join now to see all
Grant Support
- Tumor membrane vesicle (TMV) vaccine immunotherapy in head and neck cancerNIH2023–2028
- Toxicity And Efficacy Of GOLD Nanoparticle Photothermal Therapy In CancerNational Cancer Institute2010–2011
- Spore In Head And Neck CancerNational Cancer Institute2007–2011
- Second Primary Tumor Prevention W/Egfr Tkis, COX-2 Inhibitors Head &Neck CancerNational Cancer Institute2007–2011
- Chemoprevention With Green TEA Polyphenon E (PPE) And Egfr-Tkis In Head And NeckNational Cancer Institute2007–2011
- Nanotherapeutics: Multifunctional Nanoparticles For Drug Delivery And TargetingNational Cancer Institute2008–2009
- Chemoprevention Of Head And Neck Cancer With ZD1839 And CelecoxibNational Cancer Institute2007–2008
- Administration CoreNational Cancer Institute2007
- Second Primary Tumor Prevention W/Egfr Tkis &Cox-2 Inhibitors In H &N CancerNational Cancer Institute2006
- Chemoprevention Of The Head And Neck Cancer With Zd1839*National Cancer Institute2005–2006
- Core--Clinical Support/BiostatisticsNational Institute Of Dental &Craniofacial Research2002–2006
- Chemoprevention Of Head And Neck CancerNational Cancer Institute2004
- Randomized Adjuvant Therapy Of Head And Neck CancerNational Cancer Institute2000–2001
- Randomized Adjuvant Therapy Of Head And Neck CancerNational Cancer Institute1998–1999
- Adjuvant Biologic Therapy For Stage III/IV Head CancerNational Cancer Institute1997–1998
Professional Memberships
- Member
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
